# Gaucher Disease: The Evolving Big Picture

## Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

Faculty Name	Disclosure
Uma Ramaswami	Grant/Research Support: Amicus, Takeda, Intrabio Consultant/Advisory Board: Sanofi, Takeda, Amicus
Tanya Collin-Histed	Grant/Research Support: Freeline, Takeda, Sanofi, Gain Therapeutics, Avrobio, Prevail, Pfizer, M6P Therapeutics Speakers Bureau/Honoraria for non-CME: Sanofi Consultant/Advisory Board: Takeda
Amy Gaviglio	Speakers Bureau/Honoraria for non-CME: Takeda, Spark Therapeutics, Orchard Therapeutics, Worldwide Clinical Trials
Ozlem Goker-Alpan	Consultant/Advisory Board: Sanofi, Takeda, Avrobio Grant/Research Support: Sparks Therapeutics, 4DMT, Prevail Therapeutics, Homology, Chiesi, Freeline
Greg Grabowski	Consultant/Advisory Board: Moderna, Prevail Therapeutics, Vanqua Bio Speakers Bureau/Honoraria for non-CME: Takeda/Shire
Reena Kartha	Grant/Research Support: Sanofi, Pfizer Inc., Takeda, Ligand Pharmaceuticals Consultant/Advisory Board: Gain Therapeutics
Priya Kishnani	Grant/Research Support: Sanofi Genzyme, Amicus Therapeutics, Pfizer, Takeda Consultant/Advisory Board: Sanofi Genzyme, Amicus Therapeutics, Maze Therapeutics, Asklepois Biopharmaceutical (AskBio), Bayer, Takeda Other (Pompe and Gaucher Disease Registry Advisory Board): Sanofi Genzyme Other (Pompe Disease Advisory Board): Amicus Therapeutics Other (Equity/Stock Options): Maze Therapeutics, Asklepois Biopharmaceutical (AskBio) Other (Advisory Board): Baebies
Nahid Tayebi	None

The PIM planners and others have nothing to disclose.

The Saterdalen & Associates, LLC planners and others have nothing to disclose.

#### Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

#### Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact Gudrun Echterhoff prior to the live event at gudrun@worldsymposia.org